@article{3111048,
    title = "Risk assessment in sepsis: a new prognostication rule by APACHE II score and serum soluble urokinase plasminogen activator receptor",
    author = "Giamarellos-Bourboulis, E.J. and Norrby-Teglund, A. and Mylona, V. and Savva, A. and Tsangaris, I. and Dimopoulou, I. and Mouktaroudi, M. and Raftogiannis, M. and Georgitsi, M. and Linnér, A. and Adamis, G. and Antonopoulou, A. and Apostolidou, E. and Chrisofos, M. and Katsenos, C. and Koutelidakis, I. and Kotzampassi, K. and Koratzanis, G. and Koupetori, M. and Kritselis, I. and Lymberopoulou, K. and Mandragos, K. and Marioli, A. and Sundén-Cullberg, J. and Mega, A. and Prekates, A. and Routsi, C. and Gogos, C. and Treutiger, C.-J. and Armaganidis, A. and Dimopoulos, G.",
    journal = "Critical Care and Resuscitation",
    year = "2012",
    volume = "16",
    number = "4",
    doi = "10.1186/cc11463",
    keywords = "urokinase receptor;  biological marker;  urokinase receptor, adult;  aged;  APACHE;  article;  cohort analysis;  controlled study;  double blind procedure;  enzyme linked immunosorbent assay;  female;  human;  major clinical study;  male;  mortality;  multivariate logistic regression analysis;  prediction;  priority journal;  prognosis;  prospective study;  protein blood level;  receiver operating characteristic;  risk assessment;  sepsis;  septic shock;  Sweden;  blood;  clinical trial;  epidemiology;  Greece;  intensive care unit;  Kaplan Meier method;  middle aged;  mortality;  multicenter study;  procedures;  regression analysis;  sepsis;  Shock, Septic, APACHE;  Biological Markers;  Double-Blind Method;  Female;  Greece;  Humans;  Intensive Care Units;  Kaplan-Meier Estimate;  Male;  Middle Aged;  Prospective Studies;  Receptors, Urokinase Plasminogen Activator;  Regression Analysis;  Risk Assessment;  ROC Curve;  Sepsis;  Shock, Septic;  Sweden",
    abstract = "Introduction: Early risk assessment is the mainstay of management of patients with sepsis. APACHE II is the gold standard prognostic stratification system. A prediction rule that aimed to improve prognostication by APACHE II with the application of serum suPAR (soluble urokinase plasminogen activator receptor) is developed.Methods: A prospective study cohort enrolled 1914 patients with sepsis including 62.2% with sepsis and 37.8% with severe sepsis/septic shock. Serum suPAR was measured in samples drawn after diagnosis by an enzyme-immunoabsorbent assay; in 367 patients sequential measurements were performed. After ROC analysis and multivariate logistic regression analysis a prediction rule for risk was developed. The rule was validated in a double-blind fashion by an independent confirmation cohort of 196 sepsis patients, predominantly severe sepsis/septic shock patients, from Sweden.Results: Serum suPAR remained stable within survivors and non-survivors for 10 days. Regression analysis showed that APACHE II ≥17 and suPAR ≥12 ng/ml were independently associated with unfavorable outcome. Four strata of risk were identified: i) APACHE II <17 and suPAR <12 ng/ml with mortality 5.5%; ii) APACHE II < 17 and suPAR ≥12 ng/ml with mortality 17.4%; iii) APACHE II ≥ 17 and suPAR <12 ng/ml with mortality 37.4%; and iv) APACHE II ≥17 and suPAR ≥12 ng/ml with mortality 51.7%. This prediction rule was confirmed by the Swedish cohort.Conclusions: A novel prediction rule with four levels of risk in sepsis based on APACHE II score and serum suPAR is proposed. Prognostication by this rule is confirmed by an independent cohort. © 2012 Giamarellos-Bourboulis et al.; licensee BioMed Central Ltd."
}